The creators of NeoStrata Company, Inc., Drs. Eugene Van Scott and Ruey Yu are internationally recognized for making the ground breaking discovery that Alpha Hydroxy Acids (AHAs) have profound beneficial effects on human skin. They discovered that AHA compounds such as Glycolic Acid and Lactic Acid are beneficial both in the treatment of dermatological conditions, encouraging cell turnover, and in stimulating prematurely aged or damaged skin to rejuvenate itself, thereby revolutionizing the treatment of aging skin.
Doctors Van Scott and Yu began working together in 1968 at Temple University in Philadelphia, sharing a mutual interest in diseases of the skin. Since more than half of all skin problems are due to difficulties in shedding and forming the stratum corneum, the doctors were determined to find ways to positively influence the formation of new layers of the skin. This partnership has spanned five decades and still continues today.
During a study to evaluate the effects of natural, physiologic type substances on patients with ichthyosis, a rare disorder with severe scaly skin, Drs. Van Scott and Yu discovered that this class of compounds has a profound effect on the development, maturation, and turnover of both normal and diseased epidermal skin. They were elated when ichthyosis patients returned with normal appearing skin where these compounds were applied. They named the compounds alpha-hydroxyacids (AHAs) and filed for their first patent (US Patent No. 3,879,537), entitled Treatment of Ichthyosiform Dermatoses, dated April 22, 1975.
Resulting from this early work was the first AHA prescription topical lotion, called Lac-Hydrin®, which was licensed to and marketed by Westwood (a division of Bristol-Myers Squibb). Lac-Hydrin® was the best-selling prescription treatment for dry skin for more than 10 years. AHAs such as Glycolic Acid and Lactic Acid continue to be broadly used in numerous products that treat dry skin.
While the initial discoveries relating to the use of AHAs were therapeutic in nature, a monumental breakthrough in the mid-1980s caused a revolution in antiaging skincare. The continuing research and clinical experience of Drs. Van Scott and Yu revealed that AHAs are not only beneficial in the treatment of dermatological conditions, but are also effective in stimulating older damaged skin to rejuvenate itself. Avon’s Anew® in the early 1990s was the first cosmetic skincare product to license the antiaging benefits of AHAs, and numerous cosmetic and pharmaceutical companies followed suit.
NeoStrata Company, Inc.
In 1988, the doctors founded NeoStrata Company, Inc. to bring their technologies and cosmeceutical formulations directly to skincare professionals, their patients, clients, and consumers. NeoStrata Company, Inc. located in Princeton, New Jersey continues their research today, developing and marketing clinically-proven, dermatologist-developed skincare brands including NeoStrata®, Exuviance®, and CoverBlend®. Today these products are sold in more than 80 countries worldwide.
The continued work of Drs. Van Scott and Yu along with NeoStrata Company, Inc. scientists has broadened the classification of Hydroxyacids to include Polyhydroxy Acids, such as Gluconolactone, and Polyhydroxy Bionic Acids, including Lactobionic Acid and Maltobionic Acid. Both classes provide antiaging benefits and normalization of keratinization similar to traditional AHAs, but also provide additional benefits such as enhanced moisturization, antioxidant effects, and suitability for use on sensitive skin. Non-acid amino sugars such as NeoGlucosamine® also gently exfoliate to promote cell turnover, diminishing the appearance of dark spots from age or acne, reducing pore size, and improving overall clarity. Their most recent breakthrough, Aminofil®, targets the appearance of deep lines and wrinkles, scowl lines, furrow, and crow’s feet by helping to volumize the skin’s matrix.
Their collaboration continues today as they continue to work together to find treatments for skin diseases. Drs. Van Scott and Yu were awarded the 2010 Discovery Award by the Dermatology Foundation for their research discoveries and impact on the treatment of skin disease.